- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: Evotec SE to announce results for first quarter 2024 on 22 may 2024
- EQS-DD: Evotec SE: Dr. Cord Dohrmann, Restricted shares granted as Short Term Variable Incentive (Bonus) for 2023 pursuant Evotec’s remuneration system.
- EQS-News: Bayer and Evotec collaborate to advance precision cardiology
- EQS-News: Evotec presents fiscal year 2023 results and announces priority reset to focus on profitable growth
- EQS-News: Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer
- EQS-Adhoc: Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer
- EQS-News: Evotec and Variant Bio enter strategic partnership to discover and develop fibrosis treatments
- EQS-News: Evotec SE to announce results for fiscal year 2023 on 24 April 2024
- EQS-News: Evotec welcomes Aurélie Dalbiez as Chief People Officer
More ▼
Key statistics
On Friday, Evotec SE (EVTX:GER) closed at 9.76, 14.55% above the 52 week low of 8.52 set on Apr 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.14 |
---|---|
High | 10.22 |
Low | 9.75 |
Bid | 9.77 |
Offer | 9.78 |
Previous close | 10.27 |
Average volume | 1.56m |
---|---|
Shares outstanding | 177.54m |
Free float | 161.18m |
P/E (TTM) | -- |
Market cap | 1.77bn EUR |
EPS (TTM) | -0.4743 EUR |
Data delayed at least 15 minutes, as of May 17 2024 16:35 BST.
More ▼